{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343434","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-08-11T11:20:34+00:00","discovered_at":"2026-08-11T11:25:00.247947+00:00","generated_at":"2026-08-11T11:25:08.854701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tango Q2 net loss $55.3M; vopimetostat combo 92% ORR, cash $1B","bullets":["Q2 net loss $55.3M ($0.37/share) vs $38.9M ($0.35/share) YoY; cash $1.0B as of June 30, 2026.","Vopimetostat + daraxonrasib showed 92% ORR and 90% 6-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer; advancing to Phase 3.","Data to be presented at ESMO 2026 (Oct 23-27, Madrid); plans to finalize Phase 3 design in 2H 2026.","Fatma Ocak appointed Chief Commercialization Officer effective Aug 17, 2026; Robert Azelby named Chairman Aug 6, 2026.","R&D expenses $37.2M (up from $32.8M), G&A $22.6M (up from $11.3M); collaboration revenue $0 vs $3.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343434","json":"https://secwatch.observer/filing/0001193125-26-343434.json","markdown":"https://secwatch.observer/filing/0001193125-26-343434.md","text":"https://secwatch.observer/filing/0001193125-26-343434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/0001193125-26-343434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526343434/tngx-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T11:25:08.854701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}